How to buy Meridian Bioscience stock (VIVO)

Meridian Bioscience is a pharmaceuticals business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. Meridian Bioscience employs 690 staff and has a trailing 12-month revenue of around $333 million.

Our top picks for where to buy Meridian Bioscience stock

Buy Meridian Bioscience stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Meridian Bioscience stock price (NASDAQ: VIVO)

Use our graph to track the performance of VIVO stocks over time.

Meridian Bioscience shares at a glance

• Key figures

Information last updated 2024-06-30.

Latest market close	$0.00
52-week range	$0.00 - $0.00
50-day moving average more info button	$33.00
200-day moving average more info button	$31.18
Wall St. target price	$34.00
PE ratio more info button	35.3854
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$0.96

Is it a good time to buy Meridian Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Meridian Bioscience price performance over time

Historical closes compared with the close of $0 from 2023-02-14

1 week (2024-10-19)	N/A
1 month (2024-09-26)	N/A
3 months (2024-07-26)	N/A
6 months (2024-04-26)	N/A

1 year (2023-10-26)	N/A
2 years (2022-10-26)	N/A
3 years (2021-10-29)	18.81
5 years (2019-10-30)	9.74

Is Meridian Bioscience stock undervalued or overvalued?

Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Meridian Bioscience's P/E ratio

Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Meridian Bioscience shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Meridian Bioscience's PEG ratio

Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Meridian Bioscience's EBITDA

Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $92.1 million.

The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.

Meridian Bioscience financials

Revenue TTM	$333 million
Operating margin TTM	22.7%
Gross profit TTM	$188.4 million
Return on assets TTM	10.35%
Return on equity TTM	12.19%
Profit margin	12.75%
Book value	$8.41
Market Capitalization more info button	$1.5 billion

TTM: trailing 12 months

Meridian Bioscience share dividends

We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.

Have Meridian Bioscience's shares ever split?

Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007 . So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.

Meridian Bioscience share price volatility

Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.2319. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).

Meridian Bioscience overview

Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests for Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.

Frequently asked questions

What percentage of Meridian Bioscience is owned by insiders or institutions?
Currently 1.342% of Meridian Bioscience shares are held by insiders and 90.918% by institutions. How many people work for Meridian Bioscience?
Latest data suggests 690 work at Meridian Bioscience. When does the fiscal year end for Meridian Bioscience?
Meridian Bioscience's fiscal year ends in September. Where is Meridian Bioscience based?
Meridian Bioscience's address is: 3471 River Hills Drive, Cincinnati, OH, United States, 45244 What is Meridian Bioscience's ISIN number?
Meridian Bioscience's international securities identification number is: US5895841014 What is Meridian Bioscience's CUSIP number?
Meridian Bioscience's Committee on Uniform Securities Identification Procedures number is: 589602101